| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 03/02/2006 | WO2005046593A3 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
| 03/02/2006 | WO2005037210A3 Photocleavable isotope-coded affinity tags |
| 03/02/2006 | WO2005032487A3 Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus |
| 03/02/2006 | WO2005027845A3 Method of identifying cell surface molecules involved in cancer metastasis |
| 03/02/2006 | WO2005027843A3 Chronotherapeutic dosage forms |
| 03/02/2006 | WO2005013901A3 Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| 03/02/2006 | WO2005013894A3 Benzodiazepine cgrp receptor antagonists |
| 03/02/2006 | WO2005009387A3 Azepine derivatives as pharmaceutical agents |
| 03/02/2006 | WO2004112707A3 Method for purifying virus |
| 03/02/2006 | WO2004110364A3 Thiotungstate analogues and uses thereof |
| 03/02/2006 | WO2004100871A3 Combination of an aldosterone receptor antagonist and a renin inhibitor |
| 03/02/2006 | WO2004096148A3 Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
| 03/02/2006 | WO2004078118A3 Protein kinase c inhibitor, related composition, and method of use |
| 03/02/2006 | WO2004069169A3 Localized drug delivery using drug-loaded nanocapsules and implantable device coated with the same |
| 03/02/2006 | WO2004066933A3 Compositions and methods for treating cancer using igsf9 and liv-1 |
| 03/02/2006 | WO2004060278A3 Methods for rapid identification of pathogens in humans and animals |
| 03/02/2006 | WO2004032869A3 Identification of anti-hiv compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid |
| 03/02/2006 | US20060046980 Novel phosphorus-containing thyromimetics |
| 03/02/2006 | US20060046979 Organic compounds |
| 03/02/2006 | US20060043342 Color stabilization of hydroquinone hydroxyethyl ether products |
| 03/01/2006 | EP1629085A2 Transfection agents |
| 03/01/2006 | EP1629031A2 Crosslinkable polymeric materials and their applications |
| 03/01/2006 | EP1628999A2 Inactivators and bivalent inhibitors of glyoxalase i and methods of inhibiting tumor growth |
| 03/01/2006 | EP1628993A2 Methods and compositions for rna interference |
| 03/01/2006 | EP1628986A2 Synthesis of high molecular weight iron-saccharidic complexes |
| 03/01/2006 | EP1628974A2 Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (tace) |
| 03/01/2006 | EP1628947A2 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| 03/01/2006 | EP1628687A2 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 03/01/2006 | EP1628666A2 Compouds and uses thereof in modulating amyloid beta |
| 03/01/2006 | EP1628664A2 Polymorphic forms of naltrexone |
| 03/01/2006 | EP1628663A2 Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| 03/01/2006 | EP1628660A2 Methods and compositions for modulating serum cortisol levels |
| 03/01/2006 | EP1628657A2 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes |
| 03/01/2006 | EP1628655A2 Antiseptic compositions, methods and systems |
| 03/01/2006 | EP1628654A2 Compounds and methods for delivery of prostacyclin analogs |
| 03/01/2006 | EP1628653A2 Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system |
| 03/01/2006 | EP1628647A2 Novel lipids for transfection of nucleic acids |
| 03/01/2006 | EP1628643A2 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom |
| 03/01/2006 | EP1628639A2 Antimicrobial quaternary ammonium organosilane coatings |
| 03/01/2006 | EP1628638A2 Antibiotic composition |
| 03/01/2006 | EP1628631A2 Methods of treating hyperproliferative cell disorders |
| 03/01/2006 | EP1628629A2 Polynucleotides and polypeptides associated with the nf-kb pathway |
| 03/01/2006 | EP1628628A2 Methods of reducing an immune response |
| 03/01/2006 | EP1628624A2 Methods and compositions for interferon therapy |
| 03/01/2006 | EP1628623A2 Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors |
| 03/01/2006 | EP1628622A2 Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements |
| 03/01/2006 | EP1628620A2 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| 03/01/2006 | EP1628589A2 An improved method and apparatus for dosing single and multi-agent therapy |
| 03/01/2006 | EP1628532A2 Methods for the protection of memory and cognition |
| 03/01/2006 | EP1628531A2 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
| 03/01/2006 | EP1628530A2 Methods and compositions for the prevention and treatment of sepsis |
| 03/01/2006 | EP1551417A4 Three layer tear formulation |
| 03/01/2006 | EP1379203B1 Condom with an erectogenic composition |
| 03/01/2006 | EP1345942B1 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists |
| 03/01/2006 | EP1319007B1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/01/2006 | EP1185948B1 Method for screening and producing compound libraries |
| 03/01/2006 | CN1741813A Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing |
| 03/01/2006 | CN1741806A Compositions containing an active fraction isolated from lycium barbarum and methods of using the same |
| 03/01/2006 | CN1741784A Functional fragrance precursor |
| 03/01/2006 | CN1740198A GLP-1 derivative |
| 03/01/2006 | CN1740168A Therapeutic benzopyranone compounds used as intermediates. |
| 03/01/2006 | CN1739800A Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 03/01/2006 | CN1739527A The use of non-oral androgenic steroids in the manufacture of medicine for improving elevated sex hormone binding globulin levels |
| 03/01/2006 | CN1243735C 2-lminopyrrolidine derivatives |
| 03/01/2006 | CN1243723C N-phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD |
| 02/28/2006 | CA2382426C Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| 02/28/2006 | CA2373117C 13-methyl-erythromycin derivatives |
| 02/28/2006 | CA2347469C Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907 |
| 02/23/2006 | WO2005055931A3 Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses |
| 02/23/2006 | WO2005053614A3 Advanced indolinone based protein kinase inhibitors |
| 02/23/2006 | WO2005048953A3 Amide derivatives as kinase modulators |
| 02/23/2006 | WO2005016257A3 Process of making flowable hemostatic compositions and devices containing such compositions |
| 02/23/2006 | WO2004091549A3 Process for making alpha-substituted hydroxamic acids |
| 02/23/2006 | WO2004078137A3 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 02/23/2006 | WO2004071464A3 Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells |
| 02/23/2006 | WO2004071458A3 REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS |
| 02/23/2006 | WO2004064729A3 Treatments for snoring using injectable neuromuscular stimulators |
| 02/23/2006 | WO2004043383A3 A new target for angiogenesis and anti-angiogenesis therapy |
| 02/23/2006 | US20060041123 Antibacterial agents |
| 02/23/2006 | US20060041058 combined with bioactive agents for a variety of purposes including drug delivery and conjugation to one member of a binding pair for use in an assay |
| 02/23/2006 | US20060041023 Facially amphilic polymers and oligomers and uses thereof |
| 02/23/2006 | US20060040969 Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 isoenzyme 3A4 |
| 02/23/2006 | US20060040939 Benzamide inhibitors of the P2X, receptor |
| 02/23/2006 | US20060040851 Gag-peptide complex |
| 02/23/2006 | US20060040262 Novel compositions and methods in cancer |
| 02/23/2006 | US20060040253 Use of Smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney |
| 02/23/2006 | US20060039906 Humanized antibodies that sequester abeta peptide |
| 02/23/2006 | US20060039886 heating agent is polyvinyl amine, polyalkyleneamine or polyakylenimine |
| 02/22/2006 | EP1627883A1 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A derivatives |
| 02/22/2006 | EP1627076A2 Biological markers for diagnosing rheumatoid arthritis |
| 02/22/2006 | EP1626964A2 New benzimidazole derivatives |
| 02/22/2006 | EP1626731A2 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 02/22/2006 | EP1626729A2 Compositions and methods for symptomatic relief |
| 02/22/2006 | EP1626721A2 Carbostyril derivatives and mood stabilizers for treating mood disorders |
| 02/22/2006 | EP1626717A2 Benzimidazoles, compositions containing such compounds and methods of use |
| 02/22/2006 | EP1626712A2 Saururus cernuus compounds that inhibit cellular responses to hypoxia |
| 02/22/2006 | EP1626711A2 Compositions and methods for treating cancer |
| 02/22/2006 | EP1626708A2 Immunogenic reagents from west nile virus |
| 02/22/2006 | EP1626703A2 Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells |
| 02/22/2006 | EP1626702A2 Whitening and antioxidative cosmetic composition containing resveratrol and method for preparing the same |